DGAP-News

Epigenomics AG: Epigenomics and BioChain enter into broad strategic collaboration in China and investment into Epigenomics - Seite 2

better, simple to use and affordable screening methods.

Grace Tian, CEO of BioChain, commented: 'Based on our assessment of
Epigenomics' test and its significant market potential, we decided to
broaden our existing collaboration. We are pleased to introduce this
advanced cancer screening test to China and are convinced that the success
of this method in the planned clinical trial combined with the simplicity
of the Epi proColon(R) test will pave the way to high participation levels
in CRC screening in the Chinese population.'

Dr. Thomas Taapken, CEO/CFO of Epigenomics, stated: 'We are excited about
BioChain's commitment and vigorous approach to accelerate the development
of the Chinese CRC screening market with our biomarker. This agreement
reached today is the key initial step in translating our blood-based
screening assay into a major tool for colorectal cancer management in this
important region. We look forward to collaborating closely with our partner
BioChain.'

The parties also agreed to work together on the validation of other
methylation biomarkers in the cancer field. Epigenomics owns intellectual
property around a variety of cancer diagnostic markers for lung, prostate
and bladder cancer as well as for other solid tumors and markets a
CE-marked product for lung cancer diagnosis based on its proprietary SHOX2
biomarker. BioChain's advanced sample preparation technology is a valuable
asset for the clinical validation of Epigenomics' other DNA-methylation
cancer markers. Should the companies develop any future products, BioChain
shall have the option to acquire commercialization rights for the Chinese
market, while Epigenomics will retain rights for the rest of the World.

- Ends -

Contact Epigenomics AG

Antje Zeise, Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse1
10178 Berlin
Tel [phone]
[e-mail]
www.epigenomics.com

For US press inquiries:

Epigenomics, Inc.
9700 Great Seneca Highway Rockville
Maryland 20850
[e-mail]

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer earlier
and more accurately, leading to improved outcomes for patients.
Epigenomics' lead product, Epi proColon(R), is a blood-based test for the
early detection of colorectal cancer, which is currently marketed in Europe
and is under regulatory review by the FDA for the U.S.A. The Company's
technology and products have been validated through multiple partnerships
with leading global diagnostic companies and testing laboratories.